Aavas Financiers Regulatory Approval

Aavas Financiers Management Change

AAVAS Financiers accepted the resignation of Independent Director Soumya Rajan and HIA Ramachandran Venkatesh, and appointed Anjali Seth as Independent Director and Bharat Thakkar as HIA. A postal ballot for Seth's appointment was also approved.

Aavas Financiers Results Update

AAVAS Financiers released H1FY27 investor highlights, with net profit up 16.4% YoY to ₹3.5 billion. Figures come from a press release, not a full results statement.

Aavas Financiers Investor Presentation: Key Takeaways

H1FY27 PAT ₹3,528mn (+16.4% YoY); Q2FY27 PAT ₹1,815mn (+10.7% YoY). AUM ₹248bn (+16%), Q2 NIM 7.81%. Focus on 20% AUM growth.

Aavas Financiers Q2 FY27 Results: Net Profit ₹181.5 Cr, Up 10.7% YoY

Aavas Financiers Ltd reported revenue from operations of ₹736.3 Cr (+10.4% YoY) and net profit of ₹181.5 Cr (+10.7% YoY) for Q2 FY27.

Key figure

Net profit ₹181.5 Cr · +10.7% YoY

Aavas Financiers Employee Stock Options

Aavas Financiers granted 1,32,535 stock options to employees under its ESOP-2025 plan. No exercise price or monetary value is specified in the filing.

Aavas Financiers Debt & Borrowing: ₹7.5 Cr

Aavas Financiers completed a partial face-value redemption of Rs.7.50 Crore for its NCDs. The outstanding amount after this payment stands at Rs.52.50 Crore.

Value

₹7.50 Cr

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.